Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD4 | P01730 | 2/20 | 0.47 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.44 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8210703 | 0.88 | KMT2A (0.55) | KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL2862442 | 0.82 | ALDH1A1 (0.60) | KMT2AMEN1ALDH1A1TSHRLMNA | |
| SCHEMBL18608789 | 0.81 | MEN1 (0.58) | KMT2AMEN1 | |
| SCHEMBL14239934 | 0.81 | MEN1 (0.50) | KMT2AMEN1MAPK1 | |
| SCHEMBL27045311 | 0.81 | USP2 (0.52) | KMT2AMEN1ALDH1A1TSHROPRD1 | |
| SCHEMBL19706413 | 0.81 | HPGD (0.49) | KMT2AMEN1ALDH1A1TSHROPRD1 | |
| SCHEMBL327031 | 0.80 | L3MBTL1 (0.47) | KMT2AMEN1OPRD1OPRK1MAPK1 | |
| SCHEMBL20274773 | 0.79 | TP53 (0.50) | KMT2AMEN1TSHRGPR119 | |
| SCHEMBL3863834 | 0.79 | KMT2A (0.63) | KMT2AMEN1ALDH1A1TSHRLMNA | |
| SCHEMBL17624335 | 0.78 | CYP2D6 (0.47) | KMT2AMEN1ALDH1A1LMNANPFFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048222-A1 | Triaza Compound Immunoregulatory Agents | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO | 2009-02-19 | — | — | US | disclosed |
| US-20090048222-A1 | Triaza Compound Immunoregulatory Agents | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048222-A1 | Triaza Compound Immunoregulatory Agents | CD4, NFATC1, IKZF3 | CD4 1/4885SORT1 4792/4885HSD11B1 2740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.